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The widespread use of moxidectin (MOX), a parasiticide used in the sheep breeding, has 
induced the parasite resistance in Brazilian farms. As a consequence, the farmers often increase the 
dose and frequency of drug utilization, and disregards safety of meat or milk. In order to establish 
adequate therapeutic treatment it is necessary to know the pharmacokinetics of the drug in the 
animal’s body. Thus, high performance liquid chromatography-electrospray ionization-tandem 
mass spectrometry (HPLC-ESI-MS/MS) method was developed for the determination of MOX 
in serum lamb. Serum samples were treated with acetonitrile to precipitate proteins. A clean up 
by dispersive extraction in solid phase (SPE-d), using primary/secondary amine (PSA) and C18 
sorbents, followed by freezing was performed. Method validation presented precision (coefficient 
of variation) and accuracy (recovery%) between 1.7-6.7 and 80.0-107.3%, respectively. The limit 
of quantification (LOQ) of the method was 2.0 ng mL-1 and a linear response was obtained over a 
range of 2.0 to 100 ng mL-1. This method was successfully applied to the determination of MOX 
in serum from suffolk lamb to evaluate the pharmacokinetic profile.
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Introduction
The infections with gastrointestinal nematodes have 
constituted major obstacle to the expansion of the sheep 
industry in Brazil. The gastrointestinal parasitism is 
associated with physiological changes in animals, such 
as bowel dysfunction and nutritional stress that result in 
decreased body condition, lower weight gain and death of 
animals. Among the most important parasites that affect 
sheep flocks we can highlight the Haemonchus contortus.1 
The parasiticide agents allowed for controlling endo 
and ecto-parasites in sheep, the macrocyclic lactones, 
have been widely employed over the world because of 
its high efficiency and broad-spectrum activity.2 The 
moxidectin (MOX) (Figure 1), semisynthetic derivative 
of nemadectin, is a macrocyclic lactone obtained by the 
fermentation of Streptomyces cyanogriseus.3 In the last 
decade MOX has emerged in sheep flocks in Brazil due to its 
efficacy against a wide variety of nematodes and arthropod 
parasites, even at extremely low doses.4 However, similarly 
as occurred with other drugs, indiscriminate use of MOX 
could induce parasite resistance, affecting the efficiency 
of the drug.5 Actually, similarly to ivermectin and the 
benzimidazole, parasite resistance against MOX has been 
reported in Brazil.6 As an action of parasite resistance control, 
alternatives have been studied in order to minimize the spread 
of animal diseases and the damage to the breeding and may 
be referred: correct management and grazing, proper sheep 
nutrition, selection of resistant animals, biological control, 
use of vaccines, herbal medicine and/or the use of techniques 
for assessing the degree of infection.7
Chromatographic methods for the determination 
of MOX in plasma from different species (alpacas, 
cattle, horses, pig, rabbit and sheep) have been 
reported applying liquid chromatography coupled with 
fluorescence detection (LC-FLD) after a derivatization 
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step.8-13 Rarely are described analytical methods by using 
mass spectrometry as a detector for MOX.14 However, it 
is important to emphasize that analytical methods based 
on liquid chromatography coupled to mass spectrometry 
(HPLC-MS) are sufficiently sensitive and selective to 
quantify the compounds in very low amounts, not being 
necessary a derivatization step.
Regarding the sample preparation, most procedures 
described for MOX residue quantitation in plasma 
involve clean up steps using solid phase microextraction 
cartridges (SPME)8,11-13 and derivatization step. According 
to literature, the pharmacokinetic (PK) parameters of 
a veterinary drug vary according to the applied dose, 
animal species, type of animal and the application site, 
among others.15 In this regard, there is a lack of data 
available in the literature related to PK studies for MOX 
in lambs. Thus, based on the systems of sheep breeding in 
Brazil, the aim of this study was to evaluate the disposal 
of MOX in the serum of lambs. For that purpose, a 
simple and throughput liquid chromatography with mass 




Moxidectin (purity of 94.8%) was obtained from 
European Pharmacopoeia Reference Standard (Strabourg, 
France). The solvents used were high performance liquid 
cromatography (HPLC) grade. Acetonitrile (ACN) was 
obtained from J. T. Baker (USA). Methanol (MeOH) was 
obtained from J. T. Baker (Mexico). Triethylamine (TEA) 
(purity of 99%, grade PA) was obtained from Merck 
(Germany). Octadecyl (C18) and primary/secondary amine 
(PSA) was obtained from UCT, Inc. (USA). Water was 
purified with a Milli-Q system (Millipore, USA).
Standards solutions
Standard stock solution was prepared in ACN at 
a nominal concentration of 1.0 mg mL-1. Standard 
intermediate solution was prepared daily by appropriate 
dilution of stock solution in ACN, at a concentration of 
10 µg mL-1 and stored under refrigeration at 4 °C. The 
working solutions were prepared daily by dilution of 
intermediate solutions of MOX in the mobile phase (MP) 
used in the chromatographic separation. 
Animals and study design
The study protocol was approved by the Ethics 
Committee in the Use of Animals of the Animal Welfare 
Policy of the Federal University of Paraná (UFPR), Curitiba 
city, PR, Brazil (Protocol No. 055/2011). Serum samples 
were provided by the Laboratory of Production and 
Research in Sheep and Goats (LAPOC/UFPR), Curitiba 
city, PR, Brazil. Weaned Suffolk breed lambs (n = 6), aged 
69-83 days and body weight ranging from 32.2 to 39.0 kg, 
who had never received treatment with anthelmintic, were 
randomly selected. The animals were housed in individual 
pens with floor slatted suspended, equipped with individual 
feeders and drinkers, and fed a diet containing ryegrass hay. 
They received a single MOX subcutaneous injection at a 
dose of 0.2 mg kg-1 bw. All animals underwent a fasting 
solid of 12 h and were weighed before dose application. 
Blood samples (1.5 mL) were collected from each animal 
at 6, 12, 18, 24, 30, 36 h, and 2, 3, 5, 9, 14, 21, 28, 35, 
42 days after MOX administration. The samples were kept 
under refrigeration (4 °C) for a maximum of two hours, the 
serum was separated from whole blood by centrifugation 
at 2500 g, for 10 min, and stored in Eppendorf tubes at 
−20 °C prior to analysis.
Sample preparation
Blood serum samples (0.5 mL) were extracted with 2 mL 
of ACN, by vortexing (Quimis) for 30 s and centrifugation 
(Heraeus Multifuge 3L-R centrifuge, Thermo Scientific) 
at 13800 × g, for 5 min at 5 ºC. Using a Pasteur pipette 
the supernatant was transferred to another polypropylene 
tube of 50 mL containing dispersive-SPE, with 100 mg 
of octadecyl (C18) and 75 mg of primary and secondary 
amine exchange material (PSA). At the end, the Pasteur 
pipette was washed with 1 mL of ACN. The extracts were 
again shaken in vortex for 30 s, centrifuged (13800 × g, 
5 min, 5 °C) and refrigerated for 1 h at 4 ºC. After that, 
an aliquot of the supernatant (2.7 mL) was transferred to 
round-bottom flasks of 50 mL, the solvent was evaporated 
Figure 1. Moxidectin chemical structure.
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to dryness in a rota-evaporator at 40 °C (HB4 Basic rotating 
evaporator, IKA) and the residue was resuspended in 
0.5 mL of MP. In order to facilitate analyte resuspension, 
samples were sonicated in an ultrasonic bath for 30 s. 
The obtained solutions were filtered through a 0.45 µm 
nylon syringe filter directly into the vial for analysis in 
the high performance liquid chromatography-electrospray 
ionization-tandem mass spectrometry (HPLC-ESI-MS/MS) 
system. 
HPLC-ESI-MS/MS system conditions
The chromatographic separation was performed using 
a reverse phase analytical column C18 (50 × 2.1 mm, 
2.7 µm) Poroshel 120 EC-18 (Agilent Technologies), 
connected to a pre-column with the same stationary phase 
(30 × 2.1 mm, 2.7 µm). The chromatographic separation 
was performed at room temperature (25 °C), on a HPLC 
system (Varian) consisting of a binary pump (Varian ProStar 
210), and an automatic injector (Varian ProStar 410, Auto 
Sampler model). The HPLC was coupled to a Varian mass 
spectrometer triple quadrupole analyzer (QqQ) (Varian 
model 1200L), equipped with electrospray ionization 
source (ESI). The software Varian MS Workstation, 
version 6, was used for data acquisition. 
The MP was composed of (A) ACN and (B) MeOH:H2O 
(50:50 v/v) and TEA added in sufficient amount to obtain 
a pH equal 8. The ratio of the phases A:B was 75:25, v/v. 
The injection volume was 5 µL and the MP was pumped 
isocratically at a flow rate of 0.2 mL min-1. 
Optimized ionization conditions for MOX in the ESI 
source were established in order to obtain the higher MOX 
detectability in the mass spectrometer (MS/MS). For this 
purpose, 1.0 µg mL-1 MOX standard solution was directly 
infused in the MS/MS, using a flow rate of 20 µL min-1. 
A fine adjustment of each parameter was performed, 
obtaining the following optimum conditions: source 
temperature 50 °C, capillary voltage −85 kV, pressure 
and temperature of the desolvation gas 29 psi and 280 °C, 
respectively. The voltage of the detector was configured 
in 2000 V. The selected reaction monitoring method was 
the multiple reaction monitoring (MRM), conducted in 
the negative electrospray ionization mode. The selected 
transition ions (m/z) were 638 > 108 (quantification); 
638 > 235 (confirmation).
Method validation
The developed analytical method was in-house 
validated based on the guidelines provided by the Brazilian 
Ministry of Agriculture, Livestock and Supply and the 
European Community,16,17 which establish performance 
criteria for analytical methods for the determination of 
residues and contaminants in food of animal origin. The 
limit of quantification (LOQ) parameter was determined 
according to Shah et al.18 The validation parameters were: 
linear range and linearity, sensitivity, selectivity, intra and 
inter-day precision, accuracy and limit of quantification. 
The selectivity was evaluated by checking the lack of 
sign from interfering compounds at the MOX retention 
time, by comparison of the chromatogram obtained for 
blank samples (n = 10) with those originated from the 
blank matrix fortified with MOX (n = 10). The linearity and 
sensitivity were established through the matrix-matched 
analytical curve in eight different concentrations levels (2.0, 
5.0, 10.0, 20.0, 40.0, 60.0, 80.0 and 100.0 ng mL-1). The 
results were analyzed by the least squares method and the 
linearity expressed as the linear correlation coefficient (r). 
The precision of the method was determined in two 
steps: (i) repeatability (intra-day) and (ii) the intermediate 
precision (inter-day). The precision was evaluated in 
three fortification levels (5, 10.0 and 20.0 ng mL-1) and 
5 replicates for each level. The repeatability was expressed 
as the coefficient of variation (CV%) of the results of each 
level of fortification analyzed on the same day with the 
same sample, using the same instrument. The intermediate 
precision was expressed by the CV (%) of the results of 
the analysis performed on three different days (n = 3), by 
the same analyst using the same instrument.
The accuracy was determined as percent recovery at 
three fortification levels (5, 10.0 and 20.0 ng mL-1). Each 
fortification level was assessed using 5 replicates. LOQ was 
determined according to Shah et al.18 using eight samples 
independent of standards and determining the coefficient 
of variation (CV < 20%).
The matrix effect was evaluated by comparing the 
chromatogram area from the analyte in the fortified extract, 
with the analyte in solvent. For the calculation, results 
obtained from the fortified extract, at concentration levels 
corresponding to 20, 40, 60 ng mL-1, were compared with 
the results obtained for the same concentration levels of the 
analyte in the solvent. The analyte signal obtained from the 
extract at each concentration level was divided by the signal 
from the analyte in the solvent. There were conducted the F 
and t-Student tests and the results expressed as percentages.
Data analysis 
The curves of serum concentrations versus time obtained 
in the MOX disposition study, from each individual animal, 
were fitted with the Curve Expert Pro software, version 
2.0.3.19 PK analysis of data was performed using a one 
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compartment model and all estimated PK parameters were 
determined according to Gibaldi and Perrier20 and are 
reported as mean ± standard deviation (SD). 
Results and Discussion
Determination of moxidectin by HPLC-MS/MS
The determination of macrocyclic lactones by using 
MS/MS QqQ as the detection system can be accomplished 
by positive and negative electrospray ionization mode. 
Both of them were evaluated. Nonetheless, in the positive 
electrospray ionization mode sodium [M + Na]+ and 
potassium [M + K]+ adducts were predominantly observed 
instead the MOX protonated ion [M + H]+, which showed 
a low signal intensity, impairing quantitation limit of the 
analytical method. Sodium and potassium adduct formation 
occurs due to the facts of these ions are inherent in the 
matrix, and its monitoring is not recommended because 
they result in non-linear analytical curves.21 In the negative 
electrospray ionization mode, the mobile phase used favored 
the MOX deprotonation resulting in a significant increase in 
signal. Thus, as previously mentioned, optimized ionization 
conditions for MOX in the ESI source were established in 
order to obtain the higher MOX detectability in the mass 
spectrometer. 
The Brazilian Ministry of Agriculture, Livestock and 
Food Supply (MAPA) and the European Community (EC) 
specify that the methods employing mass spectrometric 
detection are particularly suitable to the confirmation of 
the presence of residues in food and biological samples 
by providing measurements of molecular masses and 
information on the chemical structure.16,17 The use of high 
and low resolution mass spectrometric techniques meets the 
criteria for the residue identity confirmation based on the 
system of identification points (IP), which is related to the 
amount of fragment ions. In the case of low-resolution mass 
analyzers, such as the triple quadrupole analyzers, four IPs 
are needed for identity confirmation.17 Thus, the proposed 
method achieves the 4 IP required to confirm the identity 
of MOX, by monitoring of the molecular ion (equivalent to 
1 IP) and two fragment ions (1.5 IP for each fragment ion). 
A typical chromatogram obtained for MOX by 
HPLC-ESI-MS/MS QqQ from lamb serum sample is 
presented in Figure 2.
Optimization of extraction procedure
The optimization of the sample preparation is an 
important process to achieve greater efficiency in the 
extraction of MOX from serum samples in order to obtain 
better recovery. The amount of co-extractants obtained 
after the extraction process established for veterinary drugs 
determination is a relevant parameter in laboratory routine 
not only because it can affect the method performance, 
but also for the maintenance of the analytical equipment. 
Thus, the clean-up step by SPE-d, using PSA (75 mg) and 
C18 (amounts tested 75, 100 and 150 mg) as sorbents, 
was introduced in the sample preparation step. As 
reported by Kinsella et al.22 the concomitant use of PSA 
and C18 is more effective in the clean-up extract step, if 
compared to their use in a separate manner. The amount 
of PSA used (75 mg) was based in a study carried out by 
Hashimoto et al.23 PSA sorbent has a high chelating effect, 
helping samples to get free from fatty acids present in the 
matrix.24 Our research has showed that the use of C18 
amounts greater than 100 mg are not able to improve the 
MOX recovery values. The C18 sorbent has the function to 
removing others nonpolar compounds present in the matrix. 
Freezing step (−4 °C for 1 h) was necessary to eliminate 
phospholipids that have been kept in the sample. The 
compounds are prone to produce unwanted matrix effects.
Method validation 
In terms of selectivity we verified the absence of 
interferences co-eluting with the analyte (MOX) or near 
to its retention time. The MOX showed linearity in the 
concentration range of 2.0 to 100 ng mL-1 with linear 
correlation coefficient higher than 0.99. The calculated 
Figure 2. Typical total ion chromatogram (TIC) obtained for moxidectin 
by HPLC-ESI-MS/MS QqQ from a lamb serum sample.
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values for intraday and interday precision, expressed 
as coefficient of variation (CV%), were in accordance 
with the values preconized by the EC and MAPA which 
recommend that CV values must be lower than 20% at 
concentration levels below 100 ng mL-1.16,17 The average 
values of accuracy, obtained through of recovery assays, 
also meets the requirements described in the validation 
guides that establish values between 70 to 110%. The LOQ 
was established as the lowest level concentration from the 
calibration curve (2 ng mL-1) corresponding to CV value 
of 16%.18 No significant difference (p < 0.05) was verified 
with respect to a decrease or increase of analytical signal of 
MOX in the extract in relation to MOX in solvent showing 
absence of matrix effect (Table 1).
The method validation parameters presented in Table 1 
indicate that the HPLC-ESI-MS/MS QqQ method showed 
to be adequate for the determination of MOX residues in 
the lamb serum for the pharmacokinetic study.
Pharmacokinetic study of moxidectin 
In the PK study, the first serum sample analyzed was 
related to that collected 6 h after MOX subcutaneous 
administration. The parameters that describe the kinetic 
layout of the MOX are shown in Table 2. It was verified that 
MOX concentration increased progressively until reaching a 
maximum average concentration (Cmax) of 7.4 ± 3.1 ng mL-1 
after 0.8 ± 0.2 day (Tmax). The results obtained (Figure 3) 
showed large intra specie variability. For instance, regarding 
the Cmax values the variability among lambs was between 
4.72 to 12.25 ng mL- 1. A large variability on Cmax values 
within specie was reported by Death et al.,14 which 
evaluated the MOX profile in marsupials obtaining Cmax 
values between 55.7 and 142 ng mL-1 after subcutaneous 
administration of 0.2 mg kg-1 bw, and by Hunter et al.,25 
who evaluated the profile of MOX in llamas and alpacas 
after topical administration of 0.5 mg kg-1 bw reporting 
Cmax values between 0.286 and 1.27 ng mL-1 for llamas 
and from 0.213 to 0.879 ng mL-1 for alpacas. In relation 
to other macrocyclic lactones, in sheep after subcutaneous 
administration of 0.2 mg kg-1 bw it was reported mean 
Cmax values for ivermectin and doramectin of 13 ± 1 and 
38 ± 20 µg L-1, respectively,2 and for ivermectin (0.2 mg kg-1 
bw) administered by oral route a mean Cmax values of 
5.4 ± 2.3 ng mL-1.26 Therefore, it can be concluded that 
reported data in this study and in the literature indicate that 
there is a large variability inter and intra-species related 
to MOX. 
Dupuy et al.27 studied the PK of MOX in the plasma 
of Lacaune breed lambs with body weight between 20 to 
37 kg, six months of age, after subcutaneous administration 
of 0.2 mg kg-1 bw. The Tmax reported by those authors was 
of 0.29 days, which is significantly lower than that observed 
in this study indicating, in our case, a slower passage 
to blood circulation. This fact may be related to body 
composition of the animals, since the Lacaune breed has 
greater ability to produce milk and Suffolk for meat, they 
exhibit different body composition, which may interfere 
in the PK of the drug.
The area under the concentration-time curve is 
generally considered as the most relevant for the assessment 
of the drug exposure extent. The verified value was 
78.5 ± 12.7 ng day mL-1, which is similar to that reported 
by Dupuy et al.27 in lambs (73.26 ± 25.60 ng day mL-1) and 
smaller than the reported by Escudero et al.28 in goats of the 
Murciano-Granadina breed (136 ng day mL-1), with body 
weight between 31 and 45.8 kg, and 1.5 to 3 years old. The 
lower area under the curve values obtained in the present 
study, when compared with Escuredo et al.,28 may be related 
to the minor body fat storage in lambs when compared to adult 
animals.29 Previous studies have also shown that the PK of 
endectocides presents variability according to the specie.29,30
The results showed that MOX levels in serum decreased 
progressively after 24 hours post dose administration. 
Table 1. Method validation parameters for quantification of moxidectin 
in lamb serum by HPLC-ESI-MS/MS QqQ
Validation parameter
Linear range / (ng mL-1) 2.0-100.0
Linearity (r) 0.99
Sensitivity / (au mL ng-1) 274066
Matrix effect / %
20 ng mL-1 1.8
40 ng mL-1 8.0
60 ng mL-1 1.9
Limit of quantification (LOQ) / (ng mL-1) 2.0
Intraday precision (CV) / %
5.0 ng mL-1 6.7
10.0 ng mL-1 2.0
20.0 ng mL-1 1.7
Interday precision (CV) / %
5.0 ng mL-1 6.0
10.0 ng mL-1 2.1
20.0 ng mL-1 2.9
Accuracy (recovery) / %
5.0 ng mL-1 82.4-89.8
10.0 ng mL-1 80.0-98.3
20.0 ng mL-1 83.7-107.3
CV: coefficient of variation.
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The constant disposal rate was 0.004 ± 0.002 days. MOX 
elimination half-life time value was 9.0 ± 3.8 days. Thus, 
the elimination half-life of MOX in lambs was similar than 
the values reported for male cattle, body weight between 
180 and 210 kg, 10 months old (14.5 ± 1.2 days) and adult 
goats (9.9 ± 1.1 days ),28,30 that received the same dose by 
the same route of exposure. The deposit of MOX in adipose 
tissue functions as a reservoir for the drug, releasing it 
gradually into the bloodstream and contributing for its long 
half-life elimination and, consequently, to the persistence of 
the molecule activity on target parasites. Young animals, by 
presenting less body fat content, tend to store less amount 
of the compound, influencing in the storage and other PK 
parameters of the drug. Thus, our results corroborate the 
long residence time of the drug in the organism and indicate 
the need to conduct a residue depletion study to establish the 
withdrawal period in the edible tissue for MOX in lambs. 
Conclusions
The results of the validation parameters showed that the 
developed and validated analytical method was suitable for 
MOX residue quantitation in lamb serum. 
The PK parameters of MOX in lambs, after subcutaneous 
administration of 2 mg kg-1 bw, corroborate the high intra 
specie variability, slow subcutaneous absorption, slow 
release of the drug in the organism and, thus, higher 
systemic exposure, and indicate the need to conduct a 
residue depletion study to establish the withdrawal period 
in the edible tissue for MOX in lambs.
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